Law tracker
Ibogaine: the law in the United States
What federal law says about ibogaine, and what individual states have done, from the statutes, bills and official pages cited on each line. Checked 26 Oct 2026. Not legal advice.
Federal law
- Peyote and mescaline are listed in Schedule I(c) of the Controlled Substances Act, as are psilocybin, psilocyn, DMT and ibogaine. (Legal Information Institute (Cornell) reproducing the U.S. Code, current)
States that have acted
Texas
- SB 2308 (89th Legislature, author Parker) establishes a consortium to conduct FDA drug-development clinical trials with ibogaine. It was signed by the Governor and took effect on 11 June 2025. (Texas Legislature Online, 11 Jun 2025; FOX 7 Austin, Jun 2025)
- Ibogaine is Schedule I under 21 USC 812. (Legal Information Institute (Cornell) reproducing the U.S. Code, current text)
Colorado
- 'Natural medicine' means psilocybin and psilocyn. DMT and mescaline may be added only if the advisory board recommends it and regulators approve, on or after 1 June 2026. Ibogaine may be added by the same process (C.R.S. 12-170-104(12) and 44-50-103). (Colorado General Assembly, 23 May 2023)
- Psilocybin, psilocyn, DMT, mescaline, peyote and ibogaine are all Schedule I under 21 USC 812. (Legal Information Institute (Cornell) reproducing the U.S. Code, current text)
Arizona
- Arizona's budget earmarked $5 million for an ibogaine clinical study; in August 2026 the Arizona Department of Health Services awarded the grant to Barrow Neurological Institute. (KJZZ, 18 Aug 2026)
District of Columbia
- The law directs the Metropolitan Police Department to make investigation and arrest of persons 18 or older for non-commercial planting, cultivating, purchasing, transporting, distributing, possessing or using entheogenic plants and fungi among its lowest law-enforcement priorities, and covers plants and fungi containing ibogaine, DMT, mescaline, psilocybin or psilocyn. (Council of the District of Columbia, 16 Mar 2021; Council of the District of Columbia, current page)
Kentucky
- In 2026 the General Assembly enacted SB 77, creating an ibogaine research and intellectual property fund administered by the Department of Agriculture for clinical trials of ibogaine; the Governor vetoed it on 13 April 2026 and both chambers overrode the veto on 14 April 2026 (Acts Chapter 158). It does not cover psilocybin. (Kentucky General Assembly, 14 Apr 2026)
Louisiana
- The initiative's purpose is to identify academic health centers conducting clinical studies and clinical trial-enabling studies of psychedelic-assisted therapy, including ibogaine and psilocybin; it does not legalize use outside research. (Louisiana State Legislature, 23 Jun 2026; WAFB, 7 May 2026)
Massachusetts
- Question 4 (2024), which would have legalized personal and supervised use of psilocybin, psilocyn, DMT, ibogaine and mescaline, failed on 5 November 2024 with about 57% voting no. (NBC Boston, 6 Nov 2024)
Mississippi
- HB 314, the Ibogaine Drug Development Clinical Trial Act, was approved by the Governor on 26 March 2026; it authorizes the State Department of Health to select a consortium to run an ibogaine clinical trial aimed at FDA approval. (Mississippi Legislature, 26 Mar 2026)
Missouri
- In 2026 the House passed HCS HBs 1717 & 1643 (137-11), which would have required a state study of psilocybin and ibogaine therapy for veterans and first responders; it was reported do pass by a Senate committee but placed on the Senate informal calendar on 7 May 2026 and did not pass before session ended. (Missouri House of Representatives, 7 May 2026; Missouri Independent via News Tribune, 5 Apr 2026)
North Carolina
- SB 1018, the HEAL Act, filed 30 April 2026, would create a Breakthrough Therapies Research Grant Fund in DHHS for two competitive grants for in-state research on psychedelic drugs including ibogaine, MDMA and psilocybin for veterans, first responders and frontline health workers. (North Carolina General Assembly, 4 May 2026)
Ohio
- Ohio's FY 2026-27 operating budget (HB 96) created a House Ibogaine Treatment Study Committee, chaired by Rep. Justin Pizzulli, to evaluate ibogaine for substance use disorders and for veterans with PTSD, depression and mild traumatic brain injury; it held its first meeting in December 2025. (Ohio House of Representatives, 15 Dec 2025)
Oklahoma
- Oklahoma's 2026 Oklahoma Breakthrough Therapy Act (HB 3834) directs the State Department of Health, subject to available funds, to contract with a drug developer to support multistate clinical trials seeking FDA approval of ibogaine; it does not cover psilocybin and takes effect 1 November 2026. (Oklahoma Legislature, 2026; Oklahoma Legislature, 2026)
Tennessee
- The HOPE Treatment Act (SB2149/HB2075, Public Chapter 1119), signed 27 May 2026, lets Tennessee research institutions run ibogaine clinical trials under FDA investigational new drug authorization, limits administration to hospitals or qualified research facilities, and gives participants immunity for compliant trial conduct. It does not cover psilocybin. (Tennessee General Assembly, 27 May 2026)
State bills that name ibogaine
| State | Bill | What it would do | Status |
|---|---|---|---|
| Arizona | HB 28712025 (57th Legislature, 1st Regular) | appropriation; ibogaine; clinical research studyWould have appropriated state money for a clinical study of ibogaine. | Passed House; held in Senate (money later included in the budget, see facts) (Arizona State Legislature, 2025) |
| Colorado | HB26-13252026 Regular Session | Natural MedicineCreates an ibogaine research pilot program of up to five sites in the Behavioral Health Administration and changes the natural medicine advisory board. | Became law; signed act dated 4 June 2026 (Colorado General Assembly, 4 Jun 2026) |
| Georgia | SB 6312025-2026 | Veterans Mental Health Innovations ActWould have authorized state grants for FDA-approved ibogaine clinical trials for veterans. | Read and referred to Senate Health and Human Services 25 March 2026; died at end of 2025-2026 session (Georgia General Assembly, 25 Mar 2026) |
| Kentucky | SB 772026 | An Act relating to ibogaine research in the CommonwealthCreates an ibogaine research and intellectual property fund and lets the Department of Agriculture partner with a drug developer on ibogaine clinical trials. | Vetoed 13 April 2026; veto overridden 14 April 2026, became law as Acts Chapter 158 (Kentucky General Assembly, 14 Apr 2026) |
| Kentucky | SB 2402025 | An Act relating to ibogaine research in the CommonwealthWould have created an Ibogaine Research Fund and a process for private entities to apply for it. | Died in Senate Health Services Committee (Kentucky General Assembly, 20 Feb 2025) |
| Louisiana | SB 432026 | Provides relative to psychedelic-assisted therapyCreates the Psychedelic-Assisted Therapy Initiative to support clinical studies of psychedelic-assisted therapy, including psilocybin and ibogaine, for substance use and mental health conditions. | Became law without the Governor's signature, Act 956, effective 1 August 2026 (Louisiana State Legislature, 23 Jun 2026; WAFB, 7 May 2026) |
| Mississippi | HB 3142026 | Ibogaine Drug Development Clinical Trial ActAuthorizes the State Department of Health to select a consortium to conduct an ibogaine drug development clinical trial and seek FDA approval. | Signed 26 March 2026 (Mississippi Legislature, 26 Mar 2026) |
| Missouri | HB 1717 (HCS HBs 1717 & 1643)2026 | Alternative TherapiesWould require a state-funded study of psilocybin and ibogaine therapy for veterans and first responders with PTSD, depression, substance use disorders or end-of-life needs, shielding enrolled participants from prosecution. | Passed House 2 April 2026; reported do pass in Senate, placed on informal calendar 7 May 2026; died at end of session (Missouri House of Representatives, 7 May 2026; Missouri Independent via News Tribune, 5 Apr 2026) |
| Oklahoma | HB 38342026 (60th Legislature, 2nd session) | Ibogaine clinical trials; Oklahoma Breakthrough Therapy ActFunds state participation in multistate ibogaine drug development trials and bars professional discipline of medical professionals solely for recommending participation in ibogaine clinical trials; it does not address psilocybin. | Signed by the Governor 12 May 2026; effective 1 November 2026 (Oklahoma Legislature, 2026; Oklahoma Legislature, 2026) |
| Tennessee | SB2149 / HB20752025-2026 (114th General Assembly) | HOPE Treatment Act (relative to clinical trials)Authorizes Tennessee research institutions to take part in FDA-authorized ibogaine clinical trials with screening and safety protocols and criminal immunity for compliant participants. | Signed by Governor 27 May 2026, Public Chapter 1119 (Tennessee General Assembly, 27 May 2026) |
| Texas | SB 230889th Legislature (2025) | Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaineCreates a state-supported consortium framework for FDA clinical trials of ibogaine for opioid use disorder and related conditions (ibogaine, not psilocybin). | Signed by the Governor 11 June 2025, effective immediately (Texas Legislature Online, 11 Jun 2025; Texas Legislature Online, 2025) |
Law changes, US and abroad
- Texas, 11 Jun 2025: SB 2308 took effect, establishing a consortium to conduct FDA drug-development clinical trials with ibogaine. It does not legalise ibogaine treatment, which remains Schedule I under federal law. (Texas Legislature Online, 11 Jun 2025)
- Costa Rica, 27 Jan 2025: The Ministerio de Salud issued a health warning: ayahuasca and ibogaine products lack sanitary registration and are not authorised for therapeutic use, DMT is on the international and national lists of controlled substances, and any ayahuasca or ibogaine product must comply with national control and registration rules. It advised against advertising them. (Ministerio de Salud de Costa Rica, 27 Jan 2025)
- Bahamas, 2024: The Dangerous Drugs (Application) Order, 2024 applies Part IV of the Dangerous Drugs Act to the drugs in the schedules of the 1961 Single Convention and the 1971 Psychotropic Convention, which include psilocybine. (Office of the Attorney General, The Bahamas, 2024)
- Colorado, 23 May 2023: SB23-290 (Natural Medicine Regulation and Legalization) was signed. It sets up licensing of facilitators (Department of Regulatory Agencies) and natural medicine businesses (Department of Revenue), limits 'natural medicine' to psilocybin and psilocyn unless regulators add DMT, mescaline or ibogaine on or after 1 June 2026, and expressly excludes peyote. (Colorado General Assembly, 23 May 2023; Colorado General Assembly, 23 May 2023)
Outside the United States
- Costa Rica, Ibogaine: The Health Ministry warned on 27 January 2025 that ibogaine products lack sanitary registration and are not authorised for therapeutic use. source
- Mexico, Ibogaine: Not listed in the Ley General de Salud (arts. 234, 245); no ibogaine-specific regulation. Unregulated, not approved. source